当前位置： SCI文献检索 > Molecular Oncology期刊下所有文献 > Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Abstract：

:Vestibular schwannomas (VSs), the most common tumors of the cerebellopontine angle, arise from Schwann cells lining the vestibular nerve. Pharmacotherapies against VS are almost non-existent. Although the therapeutic inhibition of inflammatory modulators has been established for other neoplasms, it has not been explored in VS. A bioinformatic network analysis of all genes reported to be differentially expressed in human VS revealed a pro-inflammatory transcription factor nuclear factor-kappa B (NF-κB) as a central molecule in VS pathobiology. Assessed at the transcriptional and translational level, canonical NF-κB complex was aberrantly activated in human VS and derived VS cultures in comparison to control nerves and Schwann cells, respectively. Cultured primary VS cells and VS-derived human cell line HEI-193 were treated with specific NF-κB siRNAs, experimental NF-κB inhibitor BAY11-7082 (BAY11) and clinically relevant NF-κB inhibitor curcumin. Healthy human control Schwann cells from the great auricular nerve were also treated with BAY11 and curcumin to assess toxicity. All three treatments significantly reduced proliferation in primary VS cultures and HEI-193 cells, with siRNA, 5 μM BAY11 and 50 μM curcumin reducing average proliferation (±standard error of mean) to 62.33% ± 10.59%, 14.3 ± 9.7%, and 23.0 ± 20.9% of control primary VS cells, respectively. These treatments also induced substantial cell death. Curcumin, unlike BAY11, also affected primary Schwann cells. This work highlights NF-κB as a key modulator in VS cell proliferation and survival and demonstrates therapeutic efficacy of directly targeting NF-κB in VS.

journal_name

Mol Oncol

journal_title

Molecular oncology

authors

Dilwali S,Briët MC,Kao SY,Fujita T,Landegger LD,Platt MP,Stankovic KM

doi

10.1016/j.molonc.2015.03.009

subject

Has Abstract

pub_date

2015-08-01 00:00:00

pages

1359-70

issue

7

eissn

1574-7891

issn

1878-0261

pii

S1574-7891(15)00067-8

journal_volume

9

pub_type

杂志文章

相关文献

Molecular Oncology文献大全
  • Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

    abstract：:The promise of 'personalized cancer care' with therapies toward specific molecular aberrations has potential to improve outcomes. However, there is recognized heterogeneity within any given tumor-type from patient to patient (inter-patient heterogeneity), and within an individual (intra-patient heterogeneity) as demon...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2014.09.011

    authors： Catenacci DV

    更新日期：2015-05-01 00:00:00

  • Epigenetic alterations involved in cancer stem cell reprogramming.

    abstract：:Current hypotheses suggest that tumors originate from cells that carry out a process of "malignant reprogramming" driven by genetic and epigenetic alterations. Multiples studies reported the existence of stem-cell-like cells that acquire the ability to self-renew and are able to generate the bulk of more differentiate...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2012.10.006

    authors： Muñoz P,Iliou MS,Esteller M

    更新日期：2012-12-01 00:00:00

  • Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse.

    abstract：:Patient derived xenografts (PDXs) are increasingly appreciated models in cancer research, particularly for preclinical testing, as they reflect the patient's tumor biology more accurately than cancer cell lines. We have established a collection of 20 breast PDXs and characterized their biological and clinical features...

    journal_title：Molecular oncology

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.molonc.2013.11.010

    authors： du Manoir S,Orsetti B,Bras-Gonçalves R,Nguyen TT,Lasorsa L,Boissière F,Massemin B,Colombo PE,Bibeau F,Jacot W,Theillet C

    更新日期：2014-03-01 00:00:00

  • Activation of TNF-α/NF-κB axis enhances CRL4BDCAF11 E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells.

    abstract：:Cullin 4B, a member of the Cullins, which serve as scaffolds to facilitate the assembly of E3 ligase complexes, is aberrantly expressed in many cancers, including osteosarcoma. Recently, we observed that CUL4B forms the CRL4BDCAF11 E3 ligase, which specifically ubiquitinates and degrades the cyclin-dependent kinase (C...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12176

    authors： Zhang C,Chen B,Jiang K,Lao L,Shen H,Chen Z

    更新日期：2018-04-01 00:00:00

  • Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.

    abstract：:The presence of circulating tumor cells (CTCs) in the blood of ovarian cancer patients was shown to correlate with decreased overall survival, whereby CTCs with epithelial-mesenchymal-transition (EMT) or stem-like traits are supposed to be involved in metastatic progression and recurrence. Thus, investigating the tran...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2016.04.002

    authors： Blassl C,Kuhlmann JD,Webers A,Wimberger P,Fehm T,Neubauer H

    更新日期：2016-08-01 00:00:00

  • Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs.

    abstract：:Cigarette smoking is one of the leading risks for lung cancer and is associated with the insensitivity of non-small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, it remains undetermined whether and how cigarette smoke affects the therapeutic efficacy of...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12193

    authors： Tu CY,Cheng FJ,Chen CM,Wang SL,Hsiao YC,Chen CH,Hsia TC,He YH,Wang BW,Hsieh IS,Yeh YL,Tang CH,Chen YJ,Huang WC

    更新日期：2018-05-01 00:00:00

  • Targeting breast cancer stem cells.

    abstract：:The cancer stem cell (CSC) hypothesis postulates that tumors are maintained by a self-renewing CSC population that is also capable of differentiating into non-self-renewing cell populations that constitute the bulk of the tumor. Although, the CSC hypothesis does not directly address the cell of origin of cancer, it is...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2010.06.005

    authors： McDermott SP,Wicha MS

    更新日期：2010-10-01 00:00:00

  • Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.

    abstract：PURPOSE:Lobular carcinoma in situ (LCIS) is both a risk indicator and non-obligate precursor of invasive lobular carcinoma (ILC). We sought to characterize the transcriptomic features of LCIS and ILC, with a focus on the identification of intrinsic molecular subtypes of LCIS and the changes involved in the progression ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.12.005

    authors： Andrade VP,Morrogh M,Qin LX,Olvera N,Giri D,Muhsen S,Sakr RA,Schizas M,Ng CK,Arroyo CD,Brogi E,Viale A,Morrow M,Reis-Filho JS,King TA

    更新日期：2015-04-01 00:00:00

  • Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients.

    abstract：PURPOSE:To compare the distribution and prognostic effect of the breast cancer molecular subtypes in young and elderly breast cancer patients. PATIENTS AND METHODS:Our study population (n = 822) consisted of all early breast cancer patients primarily treated with surgery in our center between 1985 and 1996. A total of...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.03.022

    authors： de Kruijf EM,Bastiaannet E,Rubertá F,de Craen AJ,Kuppen PJ,Smit VT,van de Velde CJ,Liefers GJ

    更新日期：2014-07-01 00:00:00

  • Challenges in circulating tumor cell detection by the CellSearch system.

    abstract：:Enumeration and characterization of circulating tumor cells (CTC) hold the promise of a real time liquid biopsy. They are however present in a large background of hematopoietic cells making their isolation technically challenging. In 2004, the CellSearch system was introduced as the first and only FDA cleared method d...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2015.12.002

    authors： Andree KC,van Dalum G,Terstappen LW

    更新日期：2016-03-01 00:00:00

  • Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1.

    abstract：:The Prep1 homeodomain transcription factor is essential for embryonic development. 25% of hypomorphic Prep1(i/i) embryos, expressing the gene at 2% of the normal levels, survive pregnancy and live a normal-length life. Later in life, however, these mice develop spontaneous pre-tumoral lesions or solid tumors (lymphoma...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2010.01.001

    authors： Longobardi E,Iotti G,Di Rosa P,Mejetta S,Bianchi F,Fernandez-Diaz LC,Micali N,Nuciforo P,Lenti E,Ponzoni M,Doglioni C,Caniatti M,Di Fiore PP,Blasi F

    更新日期：2010-04-01 00:00:00

  • Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.

    abstract：:ATR-CHEK1 signalling is critical for genomic stability. ATR-CHEK1 signalling may be deregulated in breast cancer and have prognostic, predictive and therapeutic significance. We investigated ATR, CHEK1 and phosphorylated CHEK1 (Ser345) protein (pCHEK1) levels in 1712 breast cancers. ATR and CHEK1 mRNA expression was e...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.10.013

    authors： Abdel-Fatah TM,Middleton FK,Arora A,Agarwal D,Chen T,Moseley PM,Perry C,Doherty R,Chan S,Green AR,Rakha E,Ball G,Ellis IO,Curtin NJ,Madhusudan S

    更新日期：2015-03-01 00:00:00

  • Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

    abstract：:Our limited understanding of the biological impact of the whole spectrum of early breast lesions together with a lack of accurate molecular-based risk criteria for the diagnosis and assignment of prognostic significance to biopsy findings presents an important problem in the clinical management of patients harboring p...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2010.09.005

    authors： Moreira JM,Cabezón T,Gromova I,Gromov P,Timmermans-Wielenga V,Machado I,Llombart-Bosch A,Kroman N,Rank F,Celis JE

    更新日期：2010-12-01 00:00:00

  • miRNAs as radio-response biomarkers for breast cancer stem cells.

    abstract：:In breast cancer (BC), the presence of cancer stem cells (CSCs) has been related to relapse, metastasis, and radioresistance. Radiotherapy (RT) is an extended BC treatment, but is not always effective. CSCs have several mechanisms of radioresistance in place, and some miRNAs are involved in the cellular response to io...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12635

    authors： Griñán-Lisón C,Olivares-Urbano MA,Jiménez G,López-Ruiz E,Del Val C,Morata-Tarifa C,Entrena JM,González-Ramírez AR,Boulaiz H,Zurita Herrera M,Núñez MI,Marchal JA

    更新日期：2020-03-01 00:00:00

  • Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.

    abstract：:Although mutations in the phosphoinositide 3-kinase catalytic subunit (PIK3CA) are common in breast cancer, PI3K inhibitors alone have shown modest efficacy. We sought to identify additional pathways altered in PIK3CA-mutant tumors that might be targeted in combination with PI3K inhibitors. We generated two transgenic...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12053

    authors： Merino VF,Cho S,Liang X,Park S,Jin K,Chen Q,Pan D,Zahnow CA,Rein AR,Sukumar S

    更新日期：2017-05-01 00:00:00

  • The brain acid-soluble protein 1 (BASP1) interferes with the oncogenic capacity of MYC and its binding to calmodulin.

    abstract：:The MYC protein is a transcription factor with oncogenic potential controlling fundamental cellular processes such as cell proliferation, metabolism, differentiation, and apoptosis. The MYC gene is a major cancer driver, and elevated MYC protein levels are a hallmark of most human cancers. We have previously shown tha...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12636

    authors： Hartl M,Puglisi K,Nist A,Raffeiner P,Bister K

    更新日期：2020-03-01 00:00:00

  • Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.

    abstract：:Bone morphogenetic proteins (BMPs) are a group of growth factors with dual functions in cancer development and progression. Recently, certain tumor-promoting roles have been identified for selected antagonists/inhibitors (BMPIs) of this developmental pathway. A recent focus on the implication of BMP in colorectal canc...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.04.004

    authors： Karagiannis GS,Treacy A,Messenger D,Grin A,Kirsch R,Riddell RH,Diamandis EP

    更新日期：2014-10-01 00:00:00

  • Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.

    abstract：:Gene and protein expression of programmed death-ligand 1 (PD-L1) are prognostic in early breast cancer (BC), but their prognostic information is inconsistent at least in some biological subgroups. The validated prognostic gene signatures (GS) in BC are mainly based on proliferation and estrogen receptor (ER)-related g...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12654

    authors： Zerdes I,Sifakis EG,Matikas A,Chrétien S,Tobin NP,Hartman J,Rassidakis GZ,Bergh J,Foukakis T

    更新日期：2020-05-01 00:00:00

  • In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.

    abstract：:The concept of polypharmacology involves the interaction of drug molecules with multiple molecular targets. It provides a unique opportunity for the repurposing of already-approved drugs to target key factors involved in human diseases. Herein, we used an in silico target prediction algorithm to investigate the mechan...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12810

    authors： Ariey-Bonnet J,Carrasco K,Le Grand M,Hoffer L,Betzi S,Feracci M,Tsvetkov P,Devred F,Collette Y,Morelli X,Ballester P,Pasquier E

    更新日期：2020-12-01 00:00:00

  • Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.

    abstract：:Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy. Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To overcome drug resistance, we explored a promising approach based on the use of 5-aza-2'-deoxycytidine (AZA), a demethylating agent, in combina...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12070

    authors： Vitale G,Dicitore A,Pepe D,Gentilini D,Grassi ES,Borghi MO,Gelmini G,Cantone MC,Gaudenzi G,Misso G,Di Blasio AM,Hofland LJ,Caraglia M,Persani L

    更新日期：2017-08-01 00:00:00

  • Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

    abstract：:The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2016.03.004

    authors： Cignetto S,Modica C,Chiriaco C,Fontani L,Milla P,Michieli P,Comoglio PM,Vigna E

    更新日期：2016-06-01 00:00:00

  • An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.

    abstract：:Genetic alterations responsible for the initiation of cancer may serve as immediate biomarkers for early diagnosis. Plasma levels of cell-free DNA (cfDNA) in patients with cancer are higher than those in healthy individuals; however, the major technical challenge for the widespread implementation of cfDNA genotyping a...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12110

    authors： Ono Y,Sugitani A,Karasaki H,Ogata M,Nozaki R,Sasajima J,Yokochi T,Asahara S,Koizumi K,Ando K,Hironaka K,Daito T,Mizukami Y

    更新日期：2017-10-01 00:00:00

  • Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.

    abstract：:Pharmacogenomics is the study of genetic factors determining drug response or toxicity. The use of pharmacogenomics is especially desirable in oncology because the therapeutic index of oncology drugs is often narrow, the need for favorable drug response is often acute, and the consequences of drug toxicity can be life...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2012.01.005

    authors： O'Donnell PH,Ratain MJ

    更新日期：2012-04-01 00:00:00

  • DNA polymerase β deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts.

    abstract：:Short arm of chromosome 8 is a hot spot for chromosomal breaks, losses and amplifications in breast cancer. Although such genetic changes may have phenotypic consequences, the identity of candidate gene(s) remains to be clearly defined. Pol β gene is localized to chromosome 8p12-p11 and encodes a key DNA base excision...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.01.001

    authors： Abdel-Fatah TM,Russell R,Agarwal D,Moseley P,Abayomi MA,Perry C,Albarakati N,Ball G,Chan S,Caldas C,Ellis IO,Madhusudan S

    更新日期：2014-05-01 00:00:00

  • Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle.

    abstract：:Germ cell cancers (GCC) are the most frequent malignancy in young Caucasian males. GCC can consist of seminomas (SE) and non-seminomas (malignant NS: embryonal carcinoma (EC), yolk sac tumor (YS), choriocarcinoma (CH) and teratoma (TE)). Current serum-markers used for diagnosis and follow-up (AFP, hCG) are predominant...

    journal_title：Molecular oncology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.molonc.2013.08.002

    authors： Gillis AJ,Rijlaarsdam MA,Eini R,Dorssers LC,Biermann K,Murray MJ,Nicholson JC,Coleman N,Dieckmann KP,Belge G,Bullerdiek J,Xu T,Bernard N,Looijenga LH

    更新日期：2013-12-01 00:00:00

  • Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.

    abstract：:Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed prioritization of c...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12564

    authors： Di J,Zheng B,Kong Q,Jiang Y,Liu S,Yang Y,Han X,Sheng Y,Zhang Y,Cheng L,Han J

    更新日期：2019-10-01 00:00:00

  • A 17 gene panel for non-small-cell lung cancer prognosis identified through integrative epigenomic-transcriptomic analyses of hypoxia-induced epithelial-mesenchymal transition.

    abstract：:As a critical feature of the tumor microenvironment, hypoxia is known to be a potent inducer of tumor metastasis, and it has been proposed that the initial steps in metastasis involve epithelial-mesenchymal transition (EMT). The strong correlation among hypoxia, EMT, and metastasis suggests that integrative assessment...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12491

    authors： Chen YL,Zhang Y,Wang J,Chen N,Fang W,Zhong J,Liu Y,Qin R,Yu X,Sun Z,Gao F

    更新日期：2019-07-01 00:00:00

  • Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.

    abstract：:The small heat-shock protein of 27 kDa (HSP27) is highly expressed in many cancers and is associated with aggressive tumour behaviour, metastasis, poor prognosis and resistance to chemotherapy. We aimed at assessing the role of HSP27 in modulating responses to target therapies. We selected several oncogene-addicted ca...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12042

    authors： Konda JD,Olivero M,Musiani D,Lamba S,Di Renzo MF

    更新日期：2017-06-01 00:00:00

  • Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma.

    abstract：:Periampullary adenocarcinomas can be of two histological subtypes, intestinal or pancreatobiliary. The latter is more frequent and aggressive, and characterized by a prominent desmoplastic stroma, which is tightly related to the biology of the cancer, including its poor response to chemotherapy. Whereas miRNAs are kno...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2015.10.011

    authors： Sandhu V,Bowitz Lothe IM,Labori KJ,Skrede ML,Hamfjord J,Dalsgaard AM,Buanes T,Dube G,Kale MM,Sawant S,Kulkarni-Kale U,Børresen-Dale AL,Lingjærde OC,Kure EH

    更新日期：2016-02-01 00:00:00

  • Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.

    abstract：:Standard treatments for advanced high-grade serous ovarian carcinomas (HGSOCs) show significant side-effects and provide only short-term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin-embedded HGSOCs, to evalu...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.09.010

    authors： Kamieniak MM,Rico D,Milne RL,Muñoz-Repeto I,Ibáñez K,Grillo MA,Domingo S,Borrego S,Cazorla A,García-Bueno JM,Hernando S,García-Donas J,Hernández-Agudo E,Y Cajal TR,Robles-Díaz L,Márquez-Rodas I,Cusidó M,Sáez R,Lacambr

    更新日期：2015-02-01 00:00:00